Beta Cell Dysfunction
Conditions
Keywords
Retinol binding protein 4, beta cell dysfunction, glycolipid metabolism
Brief summary
Retinol binding protein 4 ( RBP4 ) is a newly discovered adipokine secreted by adipose tissue, which leads to insulin resistance ( IR ) and participates in the occurrence of T2DM. At present, it's not clear whether RBP4 can cause islet β cell dysfunction. The purpose of this study is to explore the role of serum apo-RBP4 in the pathogenesis of newly diagnosed T2DM patients.
Detailed description
In recent years, with the improvement of living standards and lifestyle changes, the incidence of type II diabetes is increasing, and T2DM has become a worldwide disease that seriously endangers people ' s health. When patients with diabetes in the middle and late, the condition is often irreversible, and early if effective treatment, help to improve the condition in a timely manner, delay the development of the disease process. Therefore, early diagnosis and treatment is the key to prevention and treatment of diabetes. Years of studies have shown that insulin resistance and β-cell dysfunction are the two major mechanisms of type II diabetes. Previous studies on the pathogenesis of type II diabetes mostly focused on insulin resistance, and there are few studies on β-cell dysfunction. Therefore, the study of islet β-cell dysfunction is extremely important. According to previous studies, the investigator found that although insulin resistance exists in type II diabetes, also exists to the same extent in many people who do not have diabetes. These people may have or do not have metabolic syndrome. Therefore, insulin resistance alone cannot be the decisive pathogenic factor of type II diabetes, and the increasing facts indicate that the abnormality of islet cells, especially islet β cells, may be the central link in the pathogenesis of type II diabetes. Obviously, insulin resistance is the initiating factor of type II diabetes, and the normal function of islet β cells is the determinant of whether type II diabetes occurs : the occurrence of insulin resistance initiates the pathogenesis of type II diabetes, but if the islet β cells can maintain its compensatory ability, type II diabetes will not occur. Once its compensatory ability decreases, type II diabetes gradually occurs. Therefore, islet β cell dysfunction is the key to the pathogenesis of type II diabetes. Exploring the harmful factors that impair β-cell function is critical for early prevention and treatment of diabetes.
Interventions
BIOLOGICALoverexpression STRA6/miRNA3
RBP4 express in patients with T2DM or not
Sponsors
Shanghai 10th People's Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Serum RBP4 level in patients with or without type 2 diabetes
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Prior to conducting any trial-related activities, including those conducted to assess the subject's eligibility Informed consent of the subject; 2. Aged 18-60 years at the time of screening; 3. The diagnosis of diabetes was defined as fasting blood glucose above 7.0mmol/ L twice on different days on a normal diet
Exclusion criteria
1. HIV, hepatitis B or C ( self-reported ) or active pulmonary tuberculosis history : 2. history of malignant tumor ; 3. Severe liver dysfunction or kidney disease ( AST or ALT \> 3 times the normal upper limit, or eGFR \< 30ml min 1.73 m2 ) ; 4. History of severe cardiovascular and cerebrovascular diseases ( angina pectoris, myocardial infarction or stroke ) in the past 6 months : 5. history of severe gastrointestinal disease or gastrointestinal surgery in the past 12 months ; 6. There are other diseases that affect glucose and lipid metabolism : hyperthyroidism, hypothyroidism, cortex Hyperalcoholism, etc. ; 7. Secondary diseases or drugs lead to obesity, including : elevated cortisol ( such as Cushing 's syndrome ), sagging Obesity caused by body and hypothalamus injury, obesity caused by weight loss drug reduction / discontinuation, etc. 8. Drugs affecting body weight or energy intake / energy expenditure were used within 3 months before screening, including : Sex steroids ( intravenous, oral or intra-articular ), tricyclic antidepressants, for psychiatric disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| RBP4 | 3 years | Retinol binding protein 4 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| BMI | 3 years | BMI=weight(kg)/heihgt(m)\^2 |
| TT | 3 years | total testosterone in mmol/L |
| FBG | 3 years | fasting blood-glucose in mmol/L |
| PBG | 3 years | postprandial blood-glucose in mmol-L |
| FINS | 3 years | fasting serum insulin in mU/L |
| PINS | 3 years | postprandial serum insulin in mU/L |
| ALT | 3 years | alanine aminotransferase in U/L |
| AST | 3 years | aspartate aminotransferase in U/L |
| UA | 3 years | Uric acid in umol/L |
| HOMA-IR | 3 years | Homeostatic model assessment insulin resistance index=FBG\*FINS/22.5 |
| HbA1c(%) | 3 years | Glycated hemoglobin |
| FT | 3 years | free testosterone (nmol/L) |
| LDL-C | 3 years | low-density lipoprotein cholesterol in mmol/L |
| HDL-C | 3 years | Hight-density lipoprotein cholesterol in mmol/L |
| FSH | 3 years | follicle-stimulating hormone in IU/L |
| TC | 3 years | Total Cholesterol(mmol/L) |
| TG | 3 years | Triglyceride(mmol/L) |
Countries
China
Outcome results
None listed